FDA approves Afrezza for pediatric diabetes patients

29 maggio 2026

Riportato dall'IA

The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.

MannKind Corporation announced the approval during a call led by CEO Michael Castagna. He described the day as a historic moment for the company, the diabetes community, and young patients. Castagna noted that founder Al Mann had long envisioned the treatment reaching children, and the company is fulfilling that goal.

Fluvoxamine eases severe fatigue in long COVID patients

31 marzo 2026 Riportato dall'IA Immagine generata dall'IA

A study shows the antidepressant fluvoxamine reduces severe fatigue in long COVID patients. In a randomized trial of 399 adults, it was compared with metformin and placebo. Physician Judith Bruchfeld describes the findings as interesting.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

01 aprile 2026 Riportato dall'IA

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Tecnologia

14 giugno 2026 20:53

FDA approves Afrezza for pediatric diabetes patients

Articoli correlati

Fluvoxamine eases severe fatigue in long COVID patients

Oral GLP-1 pill shows strong results in diabetes trial

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Dexcom outlines growth plans at 2026 investor day

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

La Francia rimborsa Mounjaro e Wegovy per l'obesità grave

Novo Nordisk heads to South African court over semaglutide copies

Three million kronor for research on mast cells in asthma

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Semaglutide shows strong weight loss results for adults over 65

Swedish team restores blood sugar control in diabetic mice

Innovative Cape Town clinic boosts outcomes for young kidney patients

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

FDA approves Travere Therapeutics' FILSPARI for FSGS

Study recommends treatment for all children with obesity

Questo sito web utilizza i cookie